rss
J Neurol Neurosurg Psychiatry 2002;72:304-309 doi:10.1136/jnnp.72.3.304
  • Original Article

Possible underascertainment of variant Creutzfeldt-Jakob disease: a systematic study

  1. C E M Hillier1,
  2. R L Salmon2,
  3. J W Neal3,
  4. D A Hilton4
  1. 1Department of Neurology, University Hospital of Wales, Heath Park, Cardiff, CF14 4XW, UK
  2. 2PHLS Communicable Disease Surveillance Centre (Wales), Abton House, Wedal Road, Cardiff, CF14 3QX, UK
  3. 3Department of Neuropathology, University Hospital of Wales College of Medicine, Heath Park, Cardiff, CF14 4XW, UK
  4. 4Department of Histopathology, Derriford, Hospital, Plymouth P6 8DH, UK
  1. Correspondence to:
 Dr C Hillier, Department of Neurology, University Hospital of Wales, Heath Park, Cardiff CF14 4XW, UK;
 Cemhillier{at}aol.com
  • Received 17 May 2001
  • Accepted 3 September 2001
  • Revised 20 August 2001

Abstract

Objectives: To predict the size of the vCJD epidemic it is important to know whether the description of cases of vCJD in 1996 represent the first cases of a new disease entity or whether detection was due to increased surveillance of CJD in humans. Detection of earlier cases would suggest a shorter incubation period and might lead to predictions of epidemic size being revised.

Methods: All certified deaths (excluding external injury and poisoning) in residents of Wales aged 15–45, between 1985 and 1995, were reviewed to detect vCJD deaths that might have been overlooked. 12 091 deaths were reviewed. “Non-specific fatal disorders compatible with vCJD” were defined. Deaths recorded to diseases other than those defined were rejected from further analysis (8769). Remaining cases (3322) were subdivided. Group A comprised deaths recorded to suicide, transport accidents, and those that could not be ascertained (ICD9 rubrics E950–959, E800–848, and 7999), a total of 2698 cases. Group B comprised deaths due to neurological disease, psychiatric disease, or substance abuse (624).

Results: For group A, remaining brain material was identified (n=218, 8.1%) and examined by routine histology and immunocytochemistry for prion protein. No cases of vCJD were detected. For group B, review of remaining clinical information was undertaken. Of 624 cases, information was available on 447 (72%). Brain tissue was examined by routine histology and immunocytochemistry in 47 (7.5%) cases. Sufficient clinical and pathological information was available to exclude all these as potential cases of vCJD.

Conclusion: Variant CJD is a new disease entity and not simply the result of better case ascertainment.

Footnotes

    Register for free content

    The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

    BMJ Careers - Latest neurology and neurosurgery jobs